Palvella Therapeutics, Inc (PVLA) Stock Forecast
PVLA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 15 analysts
- Price target
- $231.25 average of analyst targets
- Upside to target
- +92.2% from the latest close
- Next earnings
- November 10, 2026 EPS estimate $-1.63
- 52-week range
- $70.43 – $158.13
PVLA analyst ratings
15 analystsNumber of analysts at each rating.
PVLA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PVLA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.74 | −$2.31 | −$1.05 | −$1.03 | −69.3% | 13 |
| Current fiscal year (2026) | −$6.43 | −$7.84 | −$3.95 | −$3.71 | −73.3% | 13 |
| Next fiscal year (2027) | −$7.98 | −$13.52 | −$1.54 | −$6.43 | −24.1% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PVLA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 15 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 15 |
| Next fiscal year (2027) | $25.6M | $6.6M | $71.1M | 0.0% | 14 |
PVLA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PVLA revenue: reported and forecast
PVLA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.47 | −$1.74 | −$1.74 | −$1.74 | −$1.74 | +19.0% | 0 up · 1 down |
| Current fiscal year (2026) | −$5.57 | −$6.37 | −$6.37 | −$6.42 | −$6.43 | +15.5% | 0 up · 1 down |
| Next fiscal year (2027) | −$6.82 | −$7.50 | −$7.50 | −$7.50 | −$7.98 | +17.0% | 1 up · 7 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PVLA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PVLA beat in 1 of 11.
What analysts expect from PVLA
15 analysts cover Palvella Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $231.25, 92.2% above the latest close of $120.30. Analysts expect earnings of −$6.43 per share for 2026, −73.3% from a year earlier. For 2027 the average estimate is −$7.98 per share on revenue of $25.6 million. Palvella Therapeutics beat the EPS estimate in 1 of the last 11 quarters.
Related: PVLA income statement, PVLA key metrics, PVLA chart. See the PVLA stock overview for the latest quote and news.
PVLA forecast FAQ
What is Palvella Therapeutics's price target?
The average analyst price target for Palvella Therapeutics is $231.25, 92.2% above the latest close of $120.30.
Is Palvella Therapeutics a buy, hold or sell?
Of 15 analysts covering Palvella Therapeutics, 15 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Palvella Therapeutics's EPS forecast?
Analysts forecast −$6.43 per share for 2026 (range −$7.84 to −$3.95); for 2027 the estimate is −$7.98.
When does Palvella Therapeutics report earnings?
Palvella Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 10, 2026; the EPS estimate is $-1.63.
Does Palvella Therapeutics usually beat earnings estimates?
Palvella Therapeutics reported EPS at or above the analyst estimate in 1 of the last 11 quarters.